News

BioPharma Dive20h
FDA advisers pan Pfizer’s PARP drug; Sarepta to resume Duchenne study
An eight-member panel voted unanimously against wider use of Pfizer’s Talzenna in advanced prostate cancer. Elsewhere, U.K.
WHO is finalizing a new treaty that prepares for the next pandemic − but the US isn’t signing
The Conversation asked Nicole Hassoun, a professor at Binghamton University and executive director of Global Health Impact, to explain the pandemic accord, its prospects for advancing global health, ...